Form 8-K - Current report:
SEC Accession No. 0001641172-25-012481
Filing Date
2025-05-27
Accepted
2025-05-27 16:15:33
Documents
15
Period of Report
2025-05-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 52841
2 EX-3.1 ex3-1.htm EX-3.1 13132
3 EX-10.1 ex10-1.htm EX-10.1 46954
4 EX-10.2 ex10-2.htm EX-10.2 10380
  Complete submission text file 0001641172-25-012481.txt   304086

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE gtbp-20250521.xsd EX-101.SCH 3023
6 XBRL LABEL FILE gtbp-20250521_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE gtbp-20250521_pre.xml EX-101.PRE 22364
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3798
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 25988591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)